Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
RC48-ADC in HER2-positive advanced solid tumors
NCT02881190Phase 1Completed
- Sponsor
- RemeGen
- Start
- Dec 2015
- Primary completion
- Jun 2019
- Modality
- Monoclonal Antibodies, Antibody-Drug Conjugates (ADCs)
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of disitamab vedotin in solid tumor, sponsored by RemeGen. Primary endpoint: Maximal Tolerance Dose at Day 28. Started Dec 2015; status: completed.
02
Drugs
disitamab vedotin
03
Conditions
solid tumor
Beyond the preview
Go deeper on NCT02881190.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02881190.